Article
Phase 3 trial supports PCV20 in adults
Rating:
0.0
Views:
131
Likes:
1
Library:
1
Pfizer’s 20-valent pneumococcal conjugate vaccine induced robust immune responses that were comparable to other vaccines currently on the market, according to results from a phase 3, randomized, double-blind trial. “PCV20 is being developed to expand pneumococcal serotype coverage beyond PCV13,” Brandon Essink, MD, CPI, principal investigator and medical director for Meridian
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value